On April 4, 2024 Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, reported preclinical data releases for two of their compounds inhibiting the DNA-damage response (DDR) of cancer cells, including Debio 0123 [selective WEE1 inhibitor] and Debio 0432 [Selective USP1 Inhibitor] at the 2024 Annual American Association for Cancer Research (AACR) (Free AACR Whitepaper) summit in San Diego, California (Press release, Debiopharm, APR 4, 2024, View Source [SID1234641807]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Since 2017, Debiopharm has been growing its expertise in the DDR inhibitor field, firstly through its WEE1-inhibitor Debio 0123 and through the recently in-licensed asset, targeting USP1. These posters are proof of our commitment to stay at the forefront of DDR-inhibitor development and outsmart hard-to-treat cancers through synthetic lethality or other groundbreaking combinations." – Angela Zubel, Chief Development Officer at Debiopharm
AACR 2024 Poster Presentations
Debiopharm compound
Title
Presenter
Mon, April 8th
Poster display: 9:00-12:30pm
Abstract #: CT064
Poster Section: 48
Poster Board #: 14
Debio 0123
Impact of food and high gastric pH on the bioavailability of the WEE1 inhibitor Debio 0123 assessed in a
Phase 1 dose escalation study
Anne Bellon, Clinical Pharmacology Lead
Mon, April 8th
Poster display: 1:30-5:00pm
Abstract #: 3370
Poster Section: 29
Poster Board #: 27
Debio 0123
Anti-tumor activity of Debio 0123 in combination with sacituzumab govitecan in preclinical models of breast cancer
Luke Piggott, Principal Scientist
Tue, April 9th
Poster display: 1:30-5:00pm
Abstract #: 6507
Poster Section: 46
Poster Board #: 24
Debio 0123
Simulation driven identification of combination for the WEE1 inhibitor Debio 0123 results in synergistic effect with cabozantinib validated in vivo
Luke Piggott, Principal Scientist
& Turbine AI
Wed, April 10th
Poster display: 9:00-12:30pm
Abstract #: 7145
Poster Section: 23
Poster Board #: 7
Debio 0432
Identification of Debio 0432 as a potent and selective USP1 inhibitor for cancer therapy
Noemie Luong, Associate Principal Scientist
About DNA-Damage Repair (DDR)
When cells have damaged DNA, they need to undergo a repair process called DDR to be able to survive. Cancer cells rely a lot on DDR as they divide and grow uncontrollably. Inhibition of DDR, particularly in combination with other anticancer agents, prevents cancer cells from repairing their DNA, which ultimately activates a self-destruction program in cancer cells. DDR inhibitors such as Debiopharm’s WEE1 and USP1 inhibitors, are being tested in clinical and preclinical studies.